Boczar Kevin E, Faller Elliot, Zeng Wanzhen, Wang Jerry, Small Gary R, Corrales-Medina Vicente F, deKemp Robert A, Ward Natalie C, Beanlands Rob S B, MacPherson Paul, Dwivedi Girish
Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, Ottawa, ON, Canada.
School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada.
J Nucl Cardiol. 2022 Dec;29(6):3057-3068. doi: 10.1007/s12350-021-02830-4. Epub 2021 Nov 24.
This study aimed to evaluate markers of systemic as well as imaging markers of inflammation in the ascending aorta, bone marrow, and spleen measured by 18F-FDG PET/CT, in HIV+ patients at baseline and following therapy with rosuvastatin.
Of the 35 HIV+ patients enrolled, 17 were randomized to treatment with 10 mg/day rosuvastatin and 18 to usual care for 6 months. An HIV- control cohort was selected for baseline comparison of serum inflammatory markers and monocyte markers of inflammation. 18F-FDG-PET/CT imaging of bone marrow, spleen, and thoracic aorta was performed in the HIV+ cohort at baseline and 6 months. While CD14++CD16- and CCR2 expressions were reduced, serum levels of IL-7, IL-8, and MCP-1 were elevated in the HIV+ population compared to the controls. There was a significant drop in FDG uptake in the bone marrow (TBR), spleen (SUV) and thoracic aortic (TBR) in the statin-treated group compared to the control group (bone marrow: - 10.3 ± 16.9% versus 5.0 ± 18.9%, p = .0262; spleen: - 9.8 ± 20.3% versus 11.3 ± 28.8%, p = .0497; thoracic aorta: - 19.1 ± 24.2% versus 4.3 ± 15.4%, p = .003).
HIV+ patients had significantly markers of systemic inflammation including monocyte activation. Treatment with low-dose rosuvastatin in the HIV+ cohort significantly reduced bone marrow, spleen and thoracic aortic FDG uptake.
本研究旨在评估通过18F-FDG PET/CT测量的HIV阳性患者基线时以及瑞舒伐他汀治疗后的全身炎症标志物以及升主动脉、骨髓和脾脏的炎症成像标志物。
在纳入的35例HIV阳性患者中，17例被随机分配接受每日10毫克瑞舒伐他汀治疗，18例接受常规治疗，为期6个月。选择一组HIV阴性对照人群用于血清炎症标志物和单核细胞炎症标志物的基线比较。对HIV阳性队列在基线时和6个月时进行骨髓、脾脏和胸主动脉的18F-FDG-PET/CT成像。与对照组相比，HIV阳性人群中CD14++CD16-和CCR2表达降低，而IL-7、IL-8和MCP-1的血清水平升高。与对照组相比，他汀类药物治疗组的骨髓（TBR）、脾脏（SUV）和胸主动脉（TBR）的FDG摄取显著下降（骨髓：-10.3±16.9%对5.0±18.9%，p = 0.0262；脾脏：-9.8±20.3%对11.3±28.8%，p = 0.0497；胸主动脉：-19.1±24.2%对4.3±15.4%，p = 0.003）。
HIV阳性患者具有包括单核细胞激活在内的显著全身炎症标志物。HIV阳性队列中低剂量瑞舒伐他汀治疗显著降低了骨髓、脾脏和胸主动脉的FDG摄取。
